[Action of a synthetic peptide on some syngeneic tumors]

Area of Science:

• Oncology
• Pharmacology
• Immunology

Context:

• Peptichemio is an established oncology drug known for low toxicity.
• Its dual alkylating and antimetabolic mechanisms are utilized in cancer treatment.
• Syngeneic mouse models are crucial for evaluating anti-cancer agents.

Purpose:

• To evaluate the protective efficacy of intraperitoneal Peptichemio against four experimental tumors in mice.
• To determine the dose-dependent activity and side-effect profile of Peptichemio.
• To assess the drug's effectiveness against specific tumor types, including plasmacytomas and adenocarcinoma.

Summary:

• Intraperitoneal Peptichemio exhibited protective effects across various experimental tumors in syngeneic mice.
• The drug was most effective against plasmacytomas and showed activity against adenocarcinoma.
• Significant efficacy was observed at both low (4 mg/Kg) and high (10 mg/Kg) doses, with minimal immunodepression and side effects at the lower dose.

Impact:

• Peptichemio demonstrates broad anti-tumor effectiveness, particularly against plasmacytomas.
• Low-dose administration offers a favorable therapeutic window with reduced immunodepression.
• Findings support Peptichemio's utility in oncology, especially for specific tumor types.